A Phase 1/2 interventional study of Intrathalamic AAV.PGRN administration and Intrathalamic AVB-101 in Frontotemporal Dementia, FTD and FTD-GRN, sponsored by AviadoBio Ltd. Recruiting at 19 sites in 9 countries. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.
Sponsored by AviadoBio Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study is to learn about an investigational gene therapy product called AVB-101, which is designed to treat a disease called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). FTD-GRN is an early-onset form of dementia, a progressive brain disorder that affects behavior, language and movement. These symptoms result from below normal levels of a protein called progranulin (PGRN) in the brain, which leads to the death of nerve cells (neurons), affecting the brain's ability to function.
The main questions that the study aims to answer are:
In this study there is no placebo (a dummy pill or treatment used for comparison purposes), so all participants will receive a one-time treatment of AVB-101 delivered directly to the brain, with follow-up assessments for 5 years.
208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.
This study's planned enrollment of 18 is below the median of 50 across 128 interventional studies indexed under Frontotemporal Dementia.
Browse Frontotemporal Dementia studies →This is the only study on the registry with AviadoBio Ltd as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initial dose
Procedure: Intrathalamic AAV.PGRN administration · Genetic: Intrathalamic AVB-101
Escalated dose
Procedure: Intrathalamic AAV.PGRN administration · Genetic: Intrathalamic AVB-101
Additional dose
Procedure: Intrathalamic AAV.PGRN administration · Genetic: Intrathalamic AVB-101
Additional dose
Procedure: Intrathalamic AAV.PGRN administration · Genetic: Intrathalamic AVB-101
One-time MRI-guided stereotaxic infusion of AAV.PGRN into the brain
AVB-101 is made from an adeno-associated virus, serotype 9 (AAV9). AAVs are small viruses that are naturally occurring and do not cause illness or infection on their own. AVB-101 has been modified to contain a copy of the correct (non-mutated) GRN gene, plus some other genetic material to enable the GRN gene to function inside neurons (cells within the brain). AVB-101 has also been modified so that it cannot divide and make new copies of itself (known as 'replication'), which means that it cannot cause disease or a large immune response in your body.
Number and incidence of AEs and SAEs
Type and incidence of adverse events
Time frame: Up to week 26
Change from baseline in the Mini-Mental State Examination (MMSE)
Mini-Mental State Examination (MMSE) is a global assessment of cognitive status. Score range 0-30; higher scores reflect better cognitive function. Change in MMSE score from baseline visit to post-treatment visit will be assessed.
Time frame: Up to week 12
Incidence of treatment emergent suicidal ideation or behavior
The Columbia-Suicide Severity Rating Scale (C-SSRS) is an assessment tool that evaluates suicidal ideation and behavior. C-SSRS will be measured at each visit to assess for absence/presence of suicidal ideation and/or behavior.
Time frame: 26 week initial, 5-year total follow-up period
Incidence of treatment-emergent clinically significant abnormalities in clinical examination findings
Time frame: 5-year total follow-up period
Incidence of treatment-emergent clinically significant abnormalities in safety laboratory values
Time frame: 5-year total follow-up period
Change from baseline in brain structure
Assessed by presence of any clinically significant MRI findings at post treatment visits including brain swelling or bleeding
Time frame: 5-year total follow-up period
Change from baseline in PGRN protein levels in CSF and blood
Change over time in level of PGRN
Time frame: 26-week initial and 5-year total follow-up period
Change from baseline in NfL levels in CSF and blood
Change over time in level of NfL
Time frame: 26-week initial and 5-year total follow-up period
Change from baseline in CDR + NACC FTLD-SB score
The Clinical Dementia Staging Instrument (CDR) plus National Alzheimer's Coordinating Center Frontotemporal Degeneration domains (NACC FTLD) was developed as a way to improve characterization of cognitive and global function in patients with FTLD. The CDR+NACC FTLD score will capture patients' disease status. CDR+NACC FTLD Sum of Boxes (SB) score refers to the sum of the scores of each domain (sum of boxes) that ranges from 0 to 24.
Time frame: 5-year total follow-up period
Time to achieve clearance of vector genomes
Measured in plasma and semen (males only)
Time frame: Up to week 26
Change from baseline in brain volumes
Calculation based upon 3DT1 MRI scans
Time frame: 5-year total follow-up period
Change from baseline in AAV9 immunogenicity in blood
Measured by level of antibodies and ELISPOT to AAV9 capsid
Time frame: 5-year total follow-up period
Change from baseline in AAV9 immunogenicity in CSF
Measured by level of antibodies to AAV9 capsid
Time frame: 5-year total follow-up period
Change from baseline in PGRN immunogenicity in CSF
Measured by level of antibodies to PGRN protein
Time frame: 5-year total follow-up period
Change from baseline in PGRN immunogenicity in blood
Measured by level of antibodies and ELISPOT to PGRN protein
Time frame: 5-year total follow-up period
Change in Caregiver Global Impression of Change (CaGI-C)
Global impression of change as assessed by the caregiver. The CaGI-C is a 7 point scale where 1= very much improved, 7= very much worse.
Time frame: 5-year total follow-up period
Change in Patient Global Impression of Change (PGI-C)
Global impression of change as assessed by the patient. The PGI-C is a 7 point scale where 1= very much improved, 7= very much worse.
Time frame: 5-year total follow-up period
Change in Clinical Global Impression of Change (CGI-C)
Global impression of change as assessed by the investigator (clinician). The CGI-C is a 7 point scale where 1= very much improved, 7= very much worse.
Time frame: 5-year total follow-up period
Change from baseline in GRN-specific Genetic Frontotemporal Initiative Cognitive (GENFI-Cog) composite score
Calculated from the neuropsychological test battery that assesses various cognitive domains: language, attention/processing speed, executive function, verbal and visuospatial memory and social cognition. Scores from the neuropsychological test battery are converted using standard statistical methods into the composite score. The GRN specific composite score is expected to be more sensitive to detect changes in cognition that are associated with FTD, and will be compared to the baseline score. Lower scores indicate worse performance.
Time frame: 5-year total follow-up period
Change from baseline in GFAP levels in CSF and blood
Change over time in level of GFAP
Time frame: 5-year total follow-up period
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Apr 2027, 43 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.